星空无限传媒

星空无限传媒
星空无限传媒 Cancer Center

Cell Therapy (CTSR)

The Cell Therapy Shared Resource provides state-of-the-art processing and production of cell therapy products for clinical use, expertise in the translation of cellular therapies to the clinic, and cutting-edge instrumentation supporting the development of novel immunotherapy strategies and insights on mechanisms of action for effective therapies.

Scheduling, Location, and Hours of Operation

Pavilion Building | Monday–Friday, 7 a.m.-6 p.m.
Extended hours are available for time-sensitive patient care needs. Questions? Contact celltherapyresearch@mcw.edu.

Services and Technologies

The CTSR provides initial project, clinical trial, and grant consultation services, free of charge, to help users understand the technical aspects, advantages, limitations, turnaround time, and cost of services.

View the FY25 CTSR price sheet (PDF)

all
Standard-of-care Clinical Processing
  • HSC processing including CD34+ selection
Cell Processing and Product Manufacturing
  • CAR T-cell manufacturing under FDA-approved IND (e.g., Miltenyi Biotec ClinicMACS Prodigy Platform)
  • 蓱/β T cell-depletion of HSC products for clinical trials
Immune Profiling
Lymphoma Cells

iLab Requests and Support

Access the links below to learn how to register for iLab and submit requests.

Leadership

headshot

Peiman Hematti, MD

Director, Cell Therapy Shared Resource (CTSR)

headshot

Tyce Kearl, MD, PhD

Co-Director, Cell Therapy Laboratory Shared Resource

tkearl@mcw.edu

View Profile

Notable Publications

(Bola帽os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators) N Engl J Med 2023 Jun 22;388(25):2338-2348 PMID 37342922 PMCID: PMC10575613 6/21/2023 SCOPUS ID: 2-s2.0-85164529275 6/21/2023

 (Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN) Haematologica 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022

 (Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN) Am J Hematol 2022 Dec;97(12):1580-1588 PMID: 36068950 DOI: 10.1002/ajh.26718 Scopus ID: 2-s2.0-85138335080 9/08/2022

 (Pulsipher MA, Ahn KW, Bunin NJ, Lalefar N, Anderson E, Flower A, Cairo MS, Talano JA, Chaudhury S, Kitko CL, Duke JL, Monos D, Leung W, Dvorak CC, Abdel-Azim H) Blood 2022 Dec 15;140(24):2556-2572 PMID: 35776909 PMCID: PMC9918850 SCOPUS ID: 2-s2.0-85144585749 7/02/2022

(Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P) Blood Cancer J. 2022 Feb 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 2/26/2022

(Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bola帽os-Meade J) J Clin Oncol 2021 Jun 20;39(18):1971-1982 PMID 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 4/28/2021

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropuli膰 B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 DOI: 10.1038/s41591-020-1081-3 SCOPUS ID: 2-s2.0-85092105030 10/07/2020